Compare Occidental Petroleum Corporation (OXY) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Occidental Petroleum Corporation vs Sana Biotechnology Inc — how do they compare? Occidental Petroleum Corporation trades at $57.7 (market cap $56.20B), while Sana Biotechnology Inc trades at $3.13 (market cap $879.40M). The key difference: Occidental Petroleum Corporation is far larger — about 63.9× Sana Biotechnology Inc's market cap, and Occidental Petroleum Corporation pays a 1.84% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| OXY | SANA | |
|---|---|---|
Market Cap | $56.20B | $879.40M |
Sector | Energy | Health |
52-Week High | $66.24 | $5.92 |
52-Week Low | $38.92 | $2.68 |
Enterprise Value | $77.28B | $853.59M |
Dividend Yield | 1.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Occidental Petroleum (OXY) trades at $56.50, up 2.99% for the day, with a bullish technical signal and strong earnings beats in recent quarters. The company maintains solid profitability with a 22.42% net income margin and robust cash flow from operations of $10.53B in 2025. Recent news highlights Permian Basin growth and capital spending cuts, while analyst consensus leans bullish with a $65.38 price target.
OXY presents upside potential driven by earnings momentum and debt reduction, but faces risks from oil price volatility and declining revenue trends. The stock's elevated P/E ratio of 74.58 warrants caution, though institutional support and strategic positioning in carbon capture technology offer long-term value. Current levels near resistance at $57 require monitoring for breakout confirmation.
SANA Biotechnology trades at $3.14, down 0.32% with a bearish technical signal. The company shows negative profitability metrics with ROE at -147.41% and net income of -$244.17M for 2025, though cash burn is projected to improve significantly in 2026. Recent positive developments include NEJM publication of groundbreaking diabetes data and multiple conference presentations highlighting clinical progress.
While analyst sentiment remains strongly bullish (82% buy ratings), the stock faces fundamental challenges with significant losses and high P/B ratio of 7.33. Investment opportunity lies in clinical pipeline advancements, but risks include ongoing cash burn and execution challenges in bringing therapies to market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Occidental Petroleum Corporation
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
